Immunome Inc. (NASDAQ: IMNM)

Immunome Inc is a clinical-stage targeted oncology company focused on developing innovative therapies to improve outcomes for cancer patients. The company leverages its expertise in antibody-drug conjugates (ADCs), radioligand therapies, and small-molecule inhibitors to build a diversified pipeline of preclinical and clinical assets. Immunome’s strategy centers on identifying novel or underexplored biological targets to address unmet needs in oncology, with a particular emphasis on rare and aggressive tumor types. Its leadership team, which includes executives with prior roles in the successful development and commercialization of ADCs, drives the advancement of a robust portfolio designed to deliver first-in-class or best-in-class therapeutic options.

Immunome generates revenue through strategic partnerships, licensing agreements, and milestone payments tied to the development and commercialization of its product candidates. While the company has not yet commercialized any therapies, its business model relies on upfront payments, royalties, and potential future sales of approved products. Key revenue streams include payments from asset acquisitions, such as the $20 million cash and $50.6 million in equity issued to Ayala Pharmaceuticals for the varegacestat program, as well as milestone-based payments tied to regulatory and developmental achievements. Additionally, Immunome may secure funding through collaborations with larger pharmaceutical companies or government grants to support its research and clinical trials.

The company operates through the following segments:

• Gamma Secretase Inhibitors: This segment focuses on varegacestat, an oral gamma secretase inhibitor currently in a Phase 3 clinical trial for the treatment of desmoid tumors. Varegacestat has demonstrated promising efficacy in earlier trials, with an objective response rate of 75% in evaluable patients and an 85% reduction in tumor cellularity. The program aims to address a rare but debilitating disease with limited treatment options, positioning varegacestat as a potential competitor to SpringWorks Therapeutics’ OGSIVEO.

• Antibody-Drug Conjugates (ADCs): This segment encompasses a pipeline of ADCs targeting solid tumors and hematologic malignancies, including IM-1021, IM-1617, IM-1340, and IM-1335. IM-1021, a receptor tyrosine kinase-like orphan receptor 1 (ROR1) ADC, is in Phase 1 trials for solid tumors and B-cell lymphomas, leveraging Immunome’s proprietary HC74 topoisomerase 1 inhibitor payload. The ADC segment is designed to overcome challenges such as tumor heterogeneity and resistance mechanisms, with a focus on novel targets to differentiate from competitors like Merck and CStone Pharmaceuticals.

• Radioligand Therapies: This segment includes IM-3050, a fibroblast activation protein (FAP)-targeted radioligand therapy for solid tumors. IM-3050 delivers radioactive lutetium-177 directly to FAP-expressing cells, leveraging a bystander effect to damage nearby tumor cells. The program aims to address limitations of existing FAP-targeted therapies, such as poor internalization, and competes with candidates from Novartis and Yantai LNC Biotechnology.

Immunome operates in the highly competitive oncology therapeutics market, where it competes with both specialized biotechnology firms and large pharmaceutical companies. Key competitors include ADC Therapeutics, Ipsen, Exelixis, Zymeworks, and Seagen (acquired by Pfizer), as well as radioligand therapy developers like RayzeBio (acquired by Bristol-Myers Squibb) and Fusion Pharmaceuticals (acquired by AstraZeneca). The company’s competitive advantages lie in its focus on underexplored biological targets, proprietary payload and linker technologies, and a leadership team with a proven track record in ADC development. Immunome’s strategy of pursuing novel targets, such as ROR1 and FAP, positions it to address gaps in the current treatment landscape, particularly for rare or aggressive cancers with limited therapeutic options.

Immunome’s customer base primarily consists of oncology patients with rare or aggressive tumor types, including desmoid tumors, B-cell lymphomas, and solid tumors such as non-small cell lung cancer, triple-negative breast cancer, and pancreatic cancer. The company’s therapies are designed to serve patients who have exhausted standard treatment options or lack effective alternatives. While Immunome does not yet have commercialized products, its future customer base will include hospitals, cancer treatment centers, and specialty pharmacies that administer oncology therapies. Additionally, the company may collaborate with diagnostic partners to develop companion diagnostics for patient selection, further refining its target market.